CN111182901A - 用于在肥厚型心肌病的治疗中使用的玛伐凯泰 - Google Patents

用于在肥厚型心肌病的治疗中使用的玛伐凯泰 Download PDF

Info

Publication number
CN111182901A
CN111182901A CN201880050881.4A CN201880050881A CN111182901A CN 111182901 A CN111182901 A CN 111182901A CN 201880050881 A CN201880050881 A CN 201880050881A CN 111182901 A CN111182901 A CN 111182901A
Authority
CN
China
Prior art keywords
compound
subject
daily dose
plasma concentration
blood plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880050881.4A
Other languages
English (en)
Chinese (zh)
Inventor
M·J·塞米格兰
J·H·李
J·兰宾
E·格林
M·埃文奇克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myokardia Inc
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Priority to CN202410743651.3A priority Critical patent/CN118593507A/zh
Publication of CN111182901A publication Critical patent/CN111182901A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
CN201880050881.4A 2017-08-04 2018-08-03 用于在肥厚型心肌病的治疗中使用的玛伐凯泰 Pending CN111182901A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410743651.3A CN118593507A (zh) 2017-08-04 2018-08-03 用于在肥厚型心肌病的治疗中使用的玛伐凯泰

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762541591P 2017-08-04 2017-08-04
US62/541,591 2017-08-04
US201762584537P 2017-11-10 2017-11-10
US62/584,537 2017-11-10
US201862639922P 2018-03-07 2018-03-07
US62/639,922 2018-03-07
US201862671585P 2018-05-15 2018-05-15
US62/671,585 2018-05-15
PCT/US2018/045180 WO2019028360A1 (en) 2017-08-04 2018-08-03 MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410743651.3A Division CN118593507A (zh) 2017-08-04 2018-08-03 用于在肥厚型心肌病的治疗中使用的玛伐凯泰

Publications (1)

Publication Number Publication Date
CN111182901A true CN111182901A (zh) 2020-05-19

Family

ID=63350605

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410743651.3A Pending CN118593507A (zh) 2017-08-04 2018-08-03 用于在肥厚型心肌病的治疗中使用的玛伐凯泰
CN201880050881.4A Pending CN111182901A (zh) 2017-08-04 2018-08-03 用于在肥厚型心肌病的治疗中使用的玛伐凯泰

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202410743651.3A Pending CN118593507A (zh) 2017-08-04 2018-08-03 用于在肥厚型心肌病的治疗中使用的玛伐凯泰

Country Status (19)

Country Link
US (5) US20200054636A1 (enExample)
EP (2) EP4659806A2 (enExample)
JP (3) JP2020529996A (enExample)
KR (2) KR20200035973A (enExample)
CN (2) CN118593507A (enExample)
AU (2) AU2018311974B2 (enExample)
CA (1) CA3071948A1 (enExample)
DK (1) DK3661514T3 (enExample)
FI (1) FI3661514T3 (enExample)
IL (2) IL322175A (enExample)
LT (1) LT3661514T (enExample)
MA (1) MA49760A (enExample)
MX (3) MX2020001406A (enExample)
MY (1) MY208231A (enExample)
RU (1) RU2020109345A (enExample)
SG (2) SG10202112960QA (enExample)
SM (1) SMT202500413T1 (enExample)
UY (1) UY37834A (enExample)
WO (1) WO2019028360A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3740481T1 (sl) 2018-01-19 2024-09-30 Cytokinetics, Inc. Analogi dihidrobenzofurana in indena kot zaviralci srčne sarkomere
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2020257609A1 (en) * 2019-06-21 2020-12-24 MyoKardia, Inc. Diagnostics and treatments for cardiac disease
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
BR112022008641A2 (pt) * 2019-11-10 2022-09-13 Myokardia Inc Métodos de tratamento com modulador de miosina
EP4480538A3 (en) * 2020-01-28 2025-04-02 Assia Chemical Industries Ltd. Solid state forms of mavacamten and process for preparation thereof
KR20230079053A (ko) * 2020-08-28 2023-06-05 미요카디아, 인크. 미오신 조절제를 이용한 치료 방법
CN119638681A (zh) 2020-11-20 2025-03-18 江苏恒瑞医药股份有限公司 三嗪二酮类衍生物、其制备方法及其在医药上的应用
WO2022162701A1 (en) * 2021-02-01 2022-08-04 Dr. Reddy's Laboratories Limited Process for preparation of mavacamten and solid state forms thereof
JP2024508526A (ja) 2021-03-04 2024-02-27 サイトキネティックス， インコーポレイテッド 心筋サルコメア阻害剤
WO2022189599A1 (en) 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
US20230058927A1 (en) * 2021-07-16 2023-02-23 Cytokinetics, Inc. Methods for treating hypertrophic cardiomyopathy
JP7732586B2 (ja) * 2021-09-24 2025-09-02 コーニンクレッカ フィリップス エヌ ヴェ 駆出率が保たれた心不全（ＨＦｐＥＦ）の尤度を生成する方法及びシステム
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
AU2024248193A1 (en) 2023-03-27 2025-10-09 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105473576A (zh) * 2013-06-21 2016-04-06 迈奥卡迪亚公司 针对心脏病症的嘧啶二酮化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105473576A (zh) * 2013-06-21 2016-04-06 迈奥卡迪亚公司 针对心脏病症的嘧啶二酮化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERIC M. GREEN等: ""A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice"", 《SCIENCE》 *
STERN, J. A.等: ""A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy"", 《PLOS ONE》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法

Also Published As

Publication number Publication date
MX2020001406A (es) 2020-03-09
SG11202000549TA (en) 2020-02-27
US20220313695A1 (en) 2022-10-06
AU2018311974A1 (en) 2020-02-06
IL272300B1 (en) 2025-08-01
US20240423981A1 (en) 2024-12-26
FI3661514T3 (fi) 2025-12-12
AU2024203872A1 (en) 2024-06-27
CA3071948A1 (en) 2019-02-07
RU2020109345A (ru) 2021-09-06
JP2025020292A (ja) 2025-02-12
DK3661514T3 (da) 2025-12-15
AU2018311974B2 (en) 2024-03-07
IL322175A (en) 2025-09-01
EP3661514A1 (en) 2020-06-10
KR20250116181A (ko) 2025-07-31
WO2019028360A1 (en) 2019-02-07
SMT202500413T1 (it) 2025-11-10
US20200054636A1 (en) 2020-02-20
CN118593507A (zh) 2024-09-06
MA49760A (fr) 2020-06-10
US20250213565A1 (en) 2025-07-03
MX2024000348A (es) 2024-01-26
JP2023065372A (ja) 2023-05-12
JP2020529996A (ja) 2020-10-15
MY208231A (en) 2025-04-25
EP3661514B1 (en) 2025-09-17
TW201916882A (zh) 2019-05-01
UY37834A (es) 2019-02-28
KR20200035973A (ko) 2020-04-06
IL272300B2 (en) 2025-12-01
SG10202112960QA (en) 2021-12-30
IL272300A (en) 2020-03-31
LT3661514T (lt) 2025-11-10
MX2024008096A (es) 2024-07-15
EP4659806A2 (en) 2025-12-10
US20220226324A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
US20250213565A1 (en) Treatment of hcm with pyrimidinedione compounds
AU2009252897B2 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
US8598225B2 (en) Use of L-butylphthalide in the manufacture of medicaments for treatment of cerebral infarct
JP2020529996A5 (enExample)
WO2009150535A1 (en) Dronedarone for the prevention of permanent atrial fibrillation
TW202320763A (zh) 治療肥厚性心肌病之方法
TW202423423A (zh) 治療非阻塞性肥厚性心肌病之方法
JP2025508069A (ja) アチカプラントを含む組成物
AU2009252898A1 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
KR20250056200A (ko) 폐쇄성 비대심장근육병증 치료 방법
JP2003267890A (ja) 不整脈および発作の治療または防止における５−ｈｔ４受容体拮抗剤の使用
JP7620758B2 (ja) 肺動脈性肺高血圧症の治療方法
HK40028703A (zh) 用於在肥厚型心肌病的治疗中使用的玛伐凯泰
JP2018135278A (ja) 循環器疾患及び／又はミトコンドリア病の改善用医薬
EP0898964A1 (en) Method for treating heart failure
US20250295639A1 (en) Methods for treating heart diseases
US20240173313A1 (en) Therapeutic tyrosine kinase inhibitors for multiple sclerosis
JP2025514817A (ja) 胃不全麻痺を処置するための重水素化ドンペリドン
JP2003509458A (ja) アレルギー状態および炎症状態の処置
WO2017153850A1 (en) Perhexiline dosing regimens for use in the treatment of hypertrophic cardiomyopathy
WO2011158178A1 (en) Use of dronedarone for the preparation of a medicament for use in the treatment of patients

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40028703

Country of ref document: HK

CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: M. J. semigran

Inventor after: J.H.Li

Inventor after: lambing Joe

Inventor after: E. Green

Inventor after: M Evan Nozick

Inventor after: T. Carlson

Inventor after: D.Zhang

Inventor before: M. J. semigran

Inventor before: J.H.Li

Inventor before: lambing Joe

Inventor before: E. Green

Inventor before: M Evan Nozick

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200519